You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 747 A phase 1 trial of IO-202, an antagonist antibody targeting myeloid checkpoint LILRB4 (ILT3), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
747 A phase 1 trial of IO-202, an antagonist antibody targeting myeloid checkpoint LILRB4 (ILT3), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to September 2024

AbstractFullPdf
Nov 2022372024
Dec 202290012
Jan 202388012
Feb 20236006
Mar 20239807
Apr 202392012
May 202384011
Jun 20239809
Jul 202374010
Aug 20236608
Sep 20236006
Oct 202312806
Nov 202380011
Dec 202398010
Jan 20246004
Feb 20244605
Mar 20245804
Apr 202488012
May 20246405
Jun 20244705
Jul 202460011
Aug 202462015
Sep 20246008
Total20330213